Greenwich LifeSciences Q3 Loss Widens to $5.8M; Cash Falls to $5.9M With Going Concern Warning
GLSI has more than doubled off its 52-week low of $7.78 on elevated volume (4.6× avg).
Summary
Greenwich LifeSciences posted a $5.8 million Q3 loss, ended September with $5.9 million in cash and negative stockholders' equity, and repeated its going concern warning.
Key Events · Earnings and Guidance · GLSI
-
Q3 Loss Widens to $5.8M
Net loss was $5,813,533 for the three months ended September 30, 2026, versus $3,711,269 a year earlier; the nine-month loss reached $15,419,345.
-
Cash Down to $5.9M
Cash fell to $5,898,582 from $6,178,021 at December 31, 2025, while net cash used in operations was $9,620,015 for the nine months.
-
Going Concern Reiterated
The filing states substantial doubt about the ability to continue as a going concern within one year and that continued operations depend on obtaining additional capital.
-
Negative Stockholders' Equity
Total stockholders' equity was $(1,746,884) at September 30, 2026, down from $353,217 at December 31, 2025, as the accumulated deficit reached $102,556,351.
Analysis · GLSI · Life Sciences
Cash burn accelerated as the quarterly loss widened to $5.8 million from $3.7 million a year earlier, leaving $5.9 million on hand against a reiterated going concern warning. With stockholders' equity now negative at $(1.7) million, the balance sheet depends entirely on raising more capital. Management also concluded disclosure controls were not effective because of material weaknesses, adding reporting-error risk on top of the funding pressure.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLSI was trading at $20.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $302.1M. The 52-week trading range was $7.78 to $34.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.